{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:52:30Z","timestamp":1793508750955,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.juro.2009.06.058","type":"journal-article","created":{"date-parts":[[2009,8,16]],"date-time":"2009-08-16T08:12:53Z","timestamp":1250410373000},"page":"1548-1554","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and Safety of Transdermal and Oral Oxybutynin in Children With Neurogenic Detrusor Overactivity"],"prefix":"10.1097","volume":"182","author":[{"given":"Patrick C.","family":"Cartwright","sequence":"first","affiliation":[{"name":"Division of Urology, University of Utah and Department of Pediatric Urology, Primary Children's Medical Center, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Coplen","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Kogan","sequence":"additional","affiliation":[{"name":"Urological Institute of Northeastern New York and Albany Medical College, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weining","family":"Volinn","sequence":"additional","affiliation":[{"name":"Watson Laboratories, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Finan","sequence":"additional","affiliation":[{"name":"Watson Laboratories, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Hoel","sequence":"additional","affiliation":[{"name":"Watson Laboratories, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2009.06.058_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1464-410X.2007.06977.x","article-title":"Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction","volume":"100","author":"Akbar","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2009.06.058_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-5347(05)63952-3","article-title":"Structural basis of neurogenic bladder dysfunction","volume":"169","author":"Haferkamp","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.06.058_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sc.1991.11","article-title":"Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride","volume":"29","author":"Madersbacher","year":"1991","journal-title":"Paraplegia"},{"key":"10.1016\/j.juro.2009.06.058_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","article-title":"Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia","volume":"75","author":"Madersbacher","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2009.06.058_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1046\/j.1464-410X.1998.00888.x","article-title":"Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder","volume":"82","author":"Amark","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2009.06.058_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1464-410X.2006.05953.x","article-title":"Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis","volume":"97","author":"Schulte-Baukloh","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2009.06.058_bib7","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/01.ju.0000176622.81796.89","article-title":"Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response","volume":"174","author":"Ellsworth","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.06.058_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.ju.0000147813.28822.d2","article-title":"Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction","volume":"173","author":"Franco","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.06.058_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/sj.sc.3100995","article-title":"Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients","volume":"38","author":"Haferkamp","year":"2000","journal-title":"Spinal Cord"},{"key":"10.1016\/j.juro.2009.06.058_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4065\/76.4.358","article-title":"Overactive Bladder: Judging Effective Control and Treatment Study Group","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.juro.2009.06.058_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","article-title":"Transdermal Oxybutynin Study Group","volume":"166","author":"Davila","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.06.058_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0090-4295(97)00489-5","article-title":"Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia","volume":"51","author":"Goessl","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.juro.2009.06.058_bib13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1464-410x.2001.02152.x","article-title":"Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida","volume":"87","author":"Ferrara","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2009.06.058_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0022-5347(17)36663-6","article-title":"The pharmacokinetics of intravesical and oral oxybutynin chloride","volume":"148","author":"Massad","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.06.058_bib15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-5347(01)65238-8","article-title":"Complications of intravesical oxybutynin chloride in the pediatric myelomeningocele population","volume":"157","author":"Palmer","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.06.058_bib16","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4065\/78.6.696","article-title":"Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects","volume":"78","author":"Appell","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.juro.2009.06.058_bib17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1010956832113","article-title":"Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers","volume":"18","author":"Zobrist","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.juro.2009.06.058_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.juro.2009.06.058_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1022259011052","article-title":"Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system","volume":"20","author":"Zobrist","year":"2003","journal-title":"Pharm Res"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534709015328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534709015328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2009.06.058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:55:33Z","timestamp":1651197333000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2009.06.058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1016\/j.juro.2009.06.058"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2009.06.058","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}